These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 1386282)

  • 1. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
    Kris MG; Tyson LB; Clark RA; Gralla RJ
    Cancer; 1992 Aug; 70(4 Suppl):1012-6. PubMed ID: 1386282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo.
    Gandara DR; Harvey WH; Monaghan GG; Perez EA; Stokes C; Bryson JC; Finn AL; Hesketh PJ
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):67-71. PubMed ID: 1387253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
    Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
    Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress in the control of acute and delayed emesis induced by cisplatin.
    Gandara DR
    Eur J Cancer; 1991; 27 Suppl 1():S9-11; discussion S22. PubMed ID: 1831633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.
    Marty M; Pouillart P; Scholl S; Droz JP; Azab M; Brion N; Pujade-Lauraine E; Paule B; Paes D; Bons J
    N Engl J Med; 1990 Mar; 322(12):816-21. PubMed ID: 2137902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
    Cubeddu LX; Hoffmann IS; Fuenmayor NT; Finn AL
    N Engl J Med; 1990 Mar; 322(12):810-6. PubMed ID: 1689807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis.
    Sorbe BG; Berglind AM; Andersson H; Boman K; Högberg T; Hallgren M; Schmidt M
    Cancer; 1998 Sep; 83(5):1022-32. PubMed ID: 9731907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
    Warr DG; Grunberg SM; Gralla RJ; Hesketh PJ; Roila F; Wit Rd; Carides AD; Taylor A; Evans JK; Horgan KJ
    Eur J Cancer; 2005 Jun; 41(9):1278-85. PubMed ID: 15939263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting.
    Marty M
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S41-5. PubMed ID: 2533898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
    Navari RM; Reinhardt RR; Gralla RJ; Kris MG; Hesketh PJ; Khojasteh A; Kindler H; Grote TH; Pendergrass K; Grunberg SM; Carides AD; Gertz BJ
    N Engl J Med; 1999 Jan; 340(3):190-5. PubMed ID: 9917226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of ondansetron-dexamethasone-lorazepam versus metoclopramide-dexamethasone-lorazepam in the control of cisplatin induced emesis.
    Manusirivithaya S; Chareoniam V; Isariyodom P; Sungsab D
    J Med Assoc Thai; 2001 Jul; 84(7):966-72. PubMed ID: 11759977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis.
    Bhatia A; Tripathi KD; Sharma M
    Indian J Med Res; 2004 Sep; 120(3):183-93. PubMed ID: 15489556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ondansetron plus dexamethasone: an effective combination in high-dose cisplatin therapy. The Italian Oncology Group for Clinical Research.
    Tonato M
    Eur J Cancer; 1991; 27 Suppl 1():S12-4; discussion S22. PubMed ID: 1831628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
    Bruntsch U; Drechsler S; Eggert J; Gosse H; Ukena D; Imhoff W; Faerber L
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical studies of oral antiemetic drugs on delayed emesis induced by cancer chemotherapy].
    Sawaguchi K; Yabushita H; Tsukada H; Yamada H; Noguchi M; Nakanishi M
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):117-23. PubMed ID: 9987507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community.
    Hickok JT; Roscoe JA; Morrow GR; King DK; Atkins JN; Fitch TR
    Cancer; 2003 Jun; 97(11):2880-6. PubMed ID: 12767103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.